Welcome
Support Centre
30 August 2008 
Current Controlled Trials - Clinical Trials
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   UKCTG  |   links  |   information  |   news
Introduction
English introduction Introduction en français Deutsche einleitung
Introducción española Introduzione in italiano
 
Find trials
active registers
UKCTG
mental health register
archived registers
all registers
tips on searching
 
Registration
submit trials
 
Information
about mRCT
mRCT FAQs
data items
memorandum
contributors

DISCLAIMER
The site should not be used to diagnose or treat a health problem. Please consult your doctor.
Terms & conditions

DUPLICATION
Your search result may contain a number of different records for the same trial. This occurs when the same trial is listed in more than one register.

[ ...Back to search results ] [ Print-friendly version ]
Adjuvant Tamoxifen Treatment - offer more? To assess reliably the balance of benefits and risks of prolonging adjuvant tamoxifen treatment by 5 years for women with breast cancer
Source of recordUK Clinical Trials Gateway
ISRCTNISRCTN17222211
Date ISRCTN assigned22/03/2001
Local reference number(s)BR3009
Public titleAdjuvant Tamoxifen Treatment - offer more? To assess reliably the balance of benefits and risks of prolonging adjuvant tamoxifen treatment by 5 years for women with breast cancer
Scientific title
AcronymaTTom
Disease/condition/study domainBreast cancer
Study hypothesisTo assess reliably, the balance of benefits and risks of prolonging adjuvant tamoxifen treatment by 5 years, in women with early breast cancer
Design/methodologyRandomised controlled trial
Research ethics reviewNot provided at time of registration
Countries of trialUnited Kingdom
Participants - inclusion criteria1. Any woman who has had complete excision of breast carcinoma
2. Any primary treatment
3. At least 2 years of prior adjuvant tamoxifen treatment (5 recommended)
4. Clinically relapse free
5. No definite indications or contraindications for further tamoxifen treatment: uncertainty as to whether further tamoxifen treatment will be of benefit
6. Where possible, ER status should be known prior to randomisation
Participants - exclusion criteriaNot provided at time of registration
Patient information material
Anticipated start date01/01/1994
Anticipated end date01/08/2014
Status of trialOngoing
Target number of participants8000
InterventionsGroup A - No further treatment with tamoxifen
Group B - At least 5 years further treatment with tamoxifen
Primary outcome measure(s)To detect or refute reliably any overall survival benefit from extending the duration of therapy with adjuvant tamoxifen
Secondary outcome measure(s)Not provided at time of registration
Sources of fundingCRC, UKCCCR, ICRF, MRC, CRUK
Sponsor nameThe University of Birmingham (UK)
Sponsor detailsEdgbaston
Birmingham
United Kingdom
B15 2TT
Contact nameMr Martin J Lee
Contact detailsBirmingham Clinical Trials Unit
University of Birmingham
Park Grange, 1 Somerset Road
Edgbaston
Birmingham
United Kingdom
B15 2RR
More informationFor more up-to-date information please go to the ISRCTN link below.
Link to record in ISRCTN RegisterISRCTN17222211
Date last extracted from ISRCTN register17/04/2008
Submit your trial protocol Top studies in medical research Submit to Trials journal
terms & conditions | privacy statement | © Current Controlled Trials Ltd


BioMed Central